$10.10 -$1.06 (-9.5%)

04:30 PM EST on 01/22/20

Evolus Inc (NASDAQ:EOLS)

CAPS Rating: No stars

Current Price $10.10 Mkt Cap $373.0M
Open $11.00 P/E Ratio 0.00
Prev. Close $11.16 Div. (Yield) $0.00 (0.0%)
Daily Range $10.00 - $11.06 Volume 1,469,568
52-Wk Range $10.00 - $13.75 Avg. Daily Vol. 659,537

Caps

How do you think NASDAQ:EOLS will perform against the market?

Add Stock to CAPS Watchlist

All Players

8 Outperform
2 Underperform
 

All-Star Players

2 Outperform
2 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:EOLS Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:EOLS VS S&P 500 (SPY)

NASDAQ:EOLS Summary

Fools bullish on NASDAQ:EOLS are also bullish on:

Fools bearish on NASDAQ:EOLS are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about EOLS.

Recs

0
Member Avatar arinab (< 20) Submitted: 2/20/2019 1:56:33 AM : Outperform Start Price: $26.47 NASDAQ:EOLS Score: -81.14

Beauty market is growing and is not constrained by government or insurance company payers. Their focus on cash paying beauty market I believe is key

Recs

0
Member Avatar Bigsef77 (68.61) Submitted: 2/4/2019 10:40:00 AM : Outperform Start Price: $28.53 NASDAQ:EOLS Score: -87.67

Evolus Surges After FDA Approves Wrinkle Treatment to Rival Allergan's Botox
Evolus surged Monday after the U.S. Food & Drug Administration approved the company's new wrinkle treatment for adult patients which is expected to be a key rival to Allergan's Botox.
Martin Baccardax
Updated Feb 4, 2019 9:40 AM EST
TheStreet

Evolus Inc. (EOLS) shares Monday after the U.S. Food & Drug Administration approved the company's new wrinkle treatment for adult patients which is expected to be a key rival to Allergan Inc.'s (AGN - Get Report) Botox.

Jeuveau received FDA approval late Friday, some eight months after the agency first rejected the application citing deficiencies in its manufacturing and chemical composition. The company has said it plans to price the treatment at discount of betwween 20% and 25% to Allergan's Botox, which generated $3.5 billion in sales last year for the Dublin, Ireland-based pharmaceutical group.

"Evolus is the first company in nearly a decade to enter the fast-growing U.S. aesthetic neurotoxin market," said CEO David Moatazedi, a former Allergan executive. "What makes Evolus unique is our focus on delivering performance beauty products with a customer-centric approach. We are pleased to introduce Jeuveau, the first FDA approved neurotoxin dedicated to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology."

Evolus shares were marked 14% higher in the opening minutes of trading Monday to change hands t $20.93 each, the highest since September 14 and a move that would value the Newport Beach, Calif.-based group at around $600 million.

Recs

0
Member Avatar PortfolioCPR (88.46) Submitted: 2/9/2018 1:16:28 AM : Outperform Start Price: $11.80 NASDAQ:EOLS Score: -41.49

First competitor to Botox

Leaderboard

Find the members with the highest scoring picks in EOLS.

Score Leader

sln

sln (67.74) Score: +76.20

The Score Leader is the player with the highest score across all their picks in EOLS.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
TheGreatSatan 99.99 12/21/2018 Underperform 5Y $11.50 -12.17% +34.32% +46.49 0 Comment
CMFBLSH 87.25 2/16/2018 Underperform 5Y $11.78 -14.26% +21.27% +35.53 0 Comment
slnoutperform < 20 1/8/2020 Outperform 5Y $10.68 -5.43% +2.63% -8.06 0 Comment
chammond55 98.49 1/9/2020 Outperform 5Y $11.85 -14.77% +1.61% -16.37 0 Comment
PortfolioCPR 88.46 2/9/2018 Outperform 5Y $11.80 -14.41% +27.08% -41.49 1 Comment
mrmrmrj 51.77 9/9/2019 Outperform 5Y $15.52 -34.92% +10.80% -45.72 0 Comment
djcrazynick 43.03 4/16/2019 Outperform 1Y $24.82 -59.31% +14.18% -73.48 0 Comment
allforone 32.31 4/22/2019 Outperform 5Y $24.99 -59.58% +14.61% -74.19 0 Comment
arinab < 20 2/20/2019 Outperform 3Y $26.47 -61.84% +19.30% -81.14 1 Comment
Bigsef77 68.61 6/28/2018 2/11/2019 Outperform 3Y $28.53 -64.60% +23.07% -87.67 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for EOLS.